Race Oncology updates our shareholders on our progress and clinical plans for 2021 and beyond.…
27
Aug
Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July 2019.
